Abstract 2284
Background
Leptomeningeal metastasis (LM) is associated with grave prognosis in breast cancer (BC) and can be treated with ventriculoperitoneal shunt (VPS). Information regarding LM and VPS based on intrinsic subtype is limited; thus, in the present study, the clinical outcomes of BC treated with VPS were investigated.
Methods
The present retrospective study included 70 patients diagnosed with LM and who received VPS. The patients were divided into four groups based on BC subtype: hormone receptor (HR)+HER2-, HR+/HER2+, HR-/HER2+, and triple negative BC (TNBC).
Results
The median age at the time of diagnosis with LM was 49 years (range 30–69 years). Isolated central nervous system (CNS) metastasis was observed in 37.1% (26/70) of patients, and more than half of the patients (47/70, 67.1%) received whole brain radiotherapy (WBRT) before and/or after VPS. The median overall survival (OS) after CNS metastasis was significantly longer in HR-/HER2+ patients (16.2 months, 95% confidence interval, CI 13.7–18.6, p = 0.009), and anti-HER2 treatment was identified as a significant prognostic factor for better OS based on multivariate analysis (hazard ratio, HR 0.15, 95% CI 0.04–0.57, p = 0.005). TNBC was correlated with shorter OS after CNS metastasis (HR 2.82, 95% CI 1.46–5.48, p = 0.002). The median OS after VPS was 2.3 months (95% CI 1.8–2.7) in all patients, and 6-months OS rates after VPS were 0% and 3.9% in HR-HER2+ and in TNBC, respectively.
Conclusions
The clinical outcome of BC patients after CNS metastasis who received VPS was significantly different in real-world clinical setting based on intrinsic subtype. Anti-HER2 treatment should be attempted after CNS metastasis in HER2+ patients. However, the survival of metastatic BC (MBC) after VPS remains poor, especially in HR-/HER2+ and TNBC subgroups. Further investigations are required to improve the prognosis of LM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yeon Hee Park.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3879 - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Presenter: Michele Droz Dit Busset
Session: Poster Display session 2
Resources:
Abstract
4679 - It’s Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia
Presenter: Ana Leonor Matos
Session: Poster Display session 2
Resources:
Abstract
2276 - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study)
Presenter: Masafumi Ikeda
Session: Poster Display session 2
Resources:
Abstract
2773 - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study
Presenter: Ulrich-Frank Pape
Session: Poster Display session 2
Resources:
Abstract
4479 - Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)
Presenter: Babita Kataria
Session: Poster Display session 2
Resources:
Abstract
4843 - FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Daniel Almquist
Session: Poster Display session 2
Resources:
Abstract
2324 - The Clinical Outcomes of Systemic Chemotherapy in Patients with Unresectable or Metastatic Combined Hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective Study of 120 Patients
Presenter: Eojin Kim
Session: Poster Display session 2
Resources:
Abstract
3678 - High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer.
Presenter: Gilhyang Kim
Session: Poster Display session 2
Resources:
Abstract
3901 - Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations
Presenter: Jingyu Cao
Session: Poster Display session 2
Resources:
Abstract
4390 - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
Presenter: Sakti Chakrabarti
Session: Poster Display session 2
Resources:
Abstract